| Grant ID | RP190672 |
| Awarded On | August 21, 2019 |
| Title | Alleviating SN-38-induced late-onset diarrhea by preserving local UGTs in the colon |
| Program | Academic Research |
| Award Mechanism | High Impact/High Risk |
| Institution/Organization | Texas Southern University |
| Principal Investigator/Program Director | Song Gao |
| Cancer Sites | Breast, Colorectal, Pancreas |
| Contracted Amount | $200,000 |
| Lay Summary |
Chemotherapy-induced diarrhea is a common side effect but is an understudied area in cancer management. This problem is especially significant with irinotecan, a prodrug of SN-38 used to treat metastatic colon cancer as well as other types of cancers (e.g., pancreatic cancer). It is reported that more than 80% of patients treated with irinotecan experienced diarrhea, with up to 40% of severe late-onset diarrhea. The overall goal of this project is to develop diarrheal biomarkers and develop preventive agents against irinotecan-induced diarrhea. We will perform a series of experiments using both in vitro and in vivo models to determine the feasibility of developing a probe for diarrhea predic... |